Welcome to Cann Pharma News.

Since its inception, Cann Pharma has established itself at the forefront of phyto-cannabinoid cultivation and development of established therapeutic treatments.

Cann Pharma is dedicated to providing and developing new cannabinoid medicines from our R&D - that address unmet patient needs and can transform lives for patients and their families.

March 30, 2020

Earthworks to level the building site for the Greenhouse and Production facility are complete. Water tanks with a volume of one million litres (4x250K tanks) plus solar power water pumps have been installed

July 1, 2019

Cann Pharma received medicinal cannabis Manufacture License from Office of Drug Control (Licence No. ML030/19)

June 5, 2019

Signed a binding term sheet with SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, to develop and supply an oral spray of pharmaceutical-grade cannabinoid derivatives

October 10, 2018

Cann Pharma received development approval from local council in NSW for an $8 million medicinal cannabis farm

September 24, 2018

Cann Pharma signs agreement for Phase 2a Drug Resistant Epilepsy clinical study, with two major hospital sites in Australia

July 11, 2018

Cann Pharma received a medicinal cannabis Import License from Office of Drug Control (Import Licence No. 1820740)

November 9, 2017

Cann Pharma received official notification of a medicinal cannabis Cultivation and Production License from Office of Drug Control

August 16, 2017

Cann Pharma submits application to Office of Drugs Control for license to manufacture medicinal cannabis

December 23, 2016

Cann Pharma signs agreement with leading contract research organisation in Australian for Phase 2a Drug Resistant Epilepsy clinical study

July 1, 2016

Cann Pharma signs agreement with Australian oncology professor for melanoma clinical study, following promising pre-clinical study results in Israel